PLXNB1 (Plexin B1) is a transmembrane receptor belonging to the plexin family, which plays a critical role in mediating cellular signaling pathways, particularly those involving semaphorins. As a high-affinity receptor for Semaphorin 4D (SEMA4D), PLXNB1 regulates diverse biological processes, including cell migration, axon guidance, immune response, and angiogenesis. Structurally, it contains a large extracellular domain for ligand binding, a transmembrane region, and an intracellular domain that interacts with downstream effectors like Rho GTPases. Dysregulation of PLXNB1 has been implicated in cancer progression, neurodevelopmental disorders, and inflammatory diseases, highlighting its therapeutic and diagnostic potential.
PLXNB1 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and flow cytometry to detect PLXNB1 in tissues or cell lines. In cancer research, PLXNB1 antibodies help elucidate its role in tumor microenvironment interactions, metastasis, and resistance to therapies. Additionally, they aid in exploring PLXNB1’s crosstalk with other signaling pathways, such as MET and ERBB2. which are often co-opted in malignancies. Recent studies also investigate PLXNB1-targeted therapies, including antibody-based inhibitors, to block SEMA4D/PLXNB1 signaling in autoimmune diseases and solid tumors. Validated for specificity and sensitivity, these antibodies remain crucial for advancing mechanistic insights and translational applications.